People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Delphinus Medical Technologies, Inc. | — | Biotechnology | Series B | $117.9M | $221.7M | 2024 |
Michael Emery at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Emery on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Gross | 1 | 9 |
| Scott White | 1 | 7 |
| Paul McCreadie | 1 | 6 |
| John Neis | 1 | 3 |
| Mark J. Forchette | 1 | 2 |
| Michael J. Fulton | 1 | 2 |
| Michael J. Gross | 1 | 2 |
| Paul J. McCreadie | 1 | 2 |
| Rachel Brem | 1 | 2 |
| Michael Fulton | 1 | 2 |
| Heather J. Rone | 1 | 1 |
| Ronald J. Ho | 1 | 1 |
| Neb J. Duric, Ph.D. | 1 | 1 |
| Debra J. Saunders | 1 | 1 |
| Shawn J. O'Brien | 1 | 1 |
| Hugo Braun | 1 | 1 |
| Ronald Ho | 1 | 1 |
| Mark Forchette | 1 | 1 |
| Elise Berman | 1 | 1 |
| Heather Rone | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.